Articles

Guest Post by David Kliff, Editor, Diabetic Investor Never let it said that this wacky world is devoid of some strange facts. Back in the day, it was discovered that exenatide was derived from Gila Monster saliva. Today GLP-1 therapy is one of the fastest growing segments of the diabetes drug market.

IDegLira, LixiLan go head-to-head; FDA approves Novo Nordisk’s Xultophy and Sanofi’s Soliqua on the same day.

Therapy shows neutral CV benefit, increases bleeding risk in type 2 diabetes.

Study finds treatment on top of stable renin angiotensin system (RAS)-inhibition decreased risk.

Study shows death rate more than five times higher than in those without the disease.

Organizations publish recommendations for identifying and reporting hypoglycemia in clinical studies.

Premarket Approval application submitted for Eversense® CGM system.

Sucralose may adversely affect glucose metabolism.

Two products approved by FDA will be available in 2017.

David Kliff, of the Diabetes Investor newsletter, attempts to explain why the cost of insulin is so high and how to solve the problem.